The Next Generation
Cancer Gene Therapy Biotech
For important risk and disclaimer information, Click here.
|
Gary Levy| Managing Director
|
|
|
|
(516) 457-0104
|
|
Tamara Williams| Managing Director
|
|
|
|
(385) 600-1871
|
Company Mission: To Conquer Cancer
Cancer gene therapy is a miraculous CURE for
cancer.
However, its $500,000 to $1,000,000 cost makes it unaffordable for most patients!
MedTherapy is on a global mission to make gene therapy affordable and accessible worldwide!
Overview
MedTherapy, Inc. (“MedTherapy” or the “Company”) is a Boston based next generation Cancer gene therapy (‘CAR-T’) biotech company founded by world class cancer experts from Harvard University & former Novartis executives.
The company is raising up to $25 million equity to grow its full spectrum, integrated, end-to-end cancer gene therapy that significantly reduces cost and time making CAR-T gene therapy affordable for all, and making MedTherapy the # 1 global manufacturing hub for gene therapies.
- Gene therapy can CURE cancer with a single dose of treatment. Therefore, gene therapy is likely how cancers and other diseases will be cured in the future
- Current Challenges: Exorbitant $500,000 to $1,000,000 cost of treatment due to manufacturing constraints, and global shortage of virus vector raw material, the most important raw material for gene therapy limiting scaling up and extremely long time to manufacture
- MedTherapy Value Proposition: The Company has developed patented technology and global manufacturing facilities reducing manufacturing costs by >70% to capture the global market
- Lowers current time of manufacture for each patient from 4-6 weeks to 2-3 days
The First Patient to be Cured of CAR-T Cancer
Gene Therapy
Emily Whitehead’s Journey
- In May 2010, little Emily Whitehead was diagnosed with childhood leukemia at the age of five years
- In April 2012 the doctor’s recommended hospice care as she was only given a few weeks to live
- Today Emily is well at 19 years of age and is a Sophomore at the University of Pennsylvania
- Emily’s treatment gained worldwide attention and helped focus public attention on the potential for cancer immunotherapy
- The founder of MedTherapy, Bikash Verma, former Medical Director at Harvard Medical School, was the medical director at Novartis when the clinical trials to treat Emily with Novartis’s CAR-T therapy were ongoing and the 1st cancer gene therapy was approved by FDA
Overview of “Personalized” Cancer Gene
Therapy Technology
On August 30, 2017 -FDA approved First ‘CAR-T’ gene therapy treatment developed by Novartis deemed as a “Cure” for
cancer.
This therapy is a ‘Personalized therapy’ which needs to be manufactured for each patient individually consuming enormous time and cost to manufacture
MedTherapy’s Key Differentiation
|
Globally accomplished founding team with expertise in next generation gene therapies |
|
Proprietary gene therapy manufacturing process |
|
Multipurpose manufacturing platform adaptable for many different types of gene therapies (Cell, Gene & Immuno therapies) |
|
Three different complimentary revenue streams including the raw materials, the viral vector |
|
Full-spectrum, end-to-end, integrated, CAR-T cell gene therapy biotech |
|
Self-sufficient with in-house production of the most critical raw materials – the viral vectors |
MedTherapy’s Solutions to CAR-T Gene
Therapy Manufacturing
- Company is manufacturing its own virus vector for gene therapies which is the engine of gene therapies to meet acute global shortages using a proprietary manufacturing technology and platform
- Global CDMO contract manufacturing for cancer gene therapy to meet global manufacturing capacity shortages
- Global scale capacity for GMP grade manufacturing
- Dramatic cost arbitrage through strategic manufacturing since ~50% of the cost of CAR-T gene therapy is manpower – making a case for labor arbitrage on a global scale
- Savings of >70% of time and cost of manufacturing
- Dramatic reduction in time from 4-6 weeks currently to 2-3 days
Traction in
Manufacturing
- Committed CAR-T biotech customers interested in partnering to manufacture cancer gene therapies
- Built the 1st gene therapy commercial global manufacturing facility in India to scale up production and begin revenue generation in Q1 2025
- Potential to become #1 gene therapy manufacturing biotech
Global Partners and Collaborators in Place
UNITED STATES:
- Harvard Medical School
- Harvard Business School
- Dana Farber Cancer Institute
- Case Western University
- Kure-AI Biotech
- AlphaGeneron Biotherapeutics
- Stanford University
EUROPE:
- Merck, Germany
- Autolus gene therapies, UK
- Flash Therapeutics, France
- Sirion Biotech, Germany
CANADA:
- Government of Canada: National Research Council
INDIA:
- TATA SONS
- Government of India: Institute of Genomics-CSIR, New Delhi
- Government of India: National Institute of Immunology, New Delhi
- Government of India: National Institute of Biologicals, Noida, U.P.
- Blood Bank Organization, New Delhi
- Artemis Hospital, Gurgaon, Haryana
- Jaypee Hospital, NOIDA
- Government Institute of Medical Sciences
- Post Graduate Institute of Medical Sciences
- All India Institute of Medical Sciences
AFRICA:
- Government of Uganda Joint Clinical Research Centre (JCRC), Uganda
Management Team
Bikash Verma, MD, DVM, MS MVSc – Chief Executive Officer & Chief Medical Officer
Boston-based renowned physician, scientist and academician who has led several pioneering global health endeavors through his tenures both in academia as well as in the biotechnology industry. Prior to leading MedTherapy, was the Medical Director at Harvard Medical School serving as a faculty and currently remains affiliated with. Previously served as the Chief Medical Officer and Medical Director at Novartis, GSK and Aurora Biopharmaceutical. President of Boston-based International Health Organization (IHO) which works in partnership with Harvard University for global health. Successfully led more than 25 clinical trials in US and globally leading to FDA registration, approval and commercial success in areas of immunology, oncology and immuno-oncology, in particular gene therapies with CAR-T. Holds multi-disciplinary and interdisciplinary specializations in three medical fields including cancer, immunology, and preventive medicine which he accomplished through doctoral degrees in medicine (MD) as well as in veterinary medicine (DVM); master’s degrees in Cancer (MS) and in preventive medicine (MVSc); and post-doctoral fellowships in immunology, completed at University of Massachusetts and affiliated hospitals, University of Illinois, S Illinois University, Birsa University, International School of Medicine, and Tufts University, among others. Serves on the board of several national and international institutions, charitable organizations, journals and biotech companies. Received several national and international awards and recognition for his accomplishments in medicine and in the service of mankind in US and globally especially in developing countries.
John Anderson, CPA, CISA, CISM, CGEIT, CITP – Chief Financial Officer (CFO)
CPA; held CFO, VP, Controller and senior executive level positions at many reputed corporations including AgaMatrix, Trinity Pharma Solutions, Paratek Pharmaceuticals, Millennium Pharmaceuticals, KPMG among others. Previously performed full service financial work in several industries including High Tech Electronics, eCommerce, Green Industrial, Pharmaceutical and Medical Devices. Given experience at companies in nascent industries, where companies can grow at exeedingly high rates, expert at devising growth plans enabling rapid roll-out of these young companies, enabling their capturing significant portions of their new and expanding markets – and hence the ideal person to lead MedTherapy. Completed undergraduate education at Babson College and subsequent graduate education and advanced trainings at Northeastern University, Suffolk University Law School and Harvard University.
Moran Ben David Shapira, JD, MBA – VP of BD, HR & Legal – VP of Business Development
Rich interdisciplinary background and skills at the cross-section of pharma drug development, biology and business and IP law from blockbuster-drugs IP litigation, to evaluation of new technologies, biological and business opportunities as well as management of collaborations worldwide. Various business strategy positions such as Head of Business Development at Pharma Two B in Israel leadership positions in global strategic partnership and alliance management at GlaxoSmithKline, Novartis, and Takeda in Boston. Established partnerships for early stage innovative projects and clinical development. Before joining the pharmaceutical industry, was a practicing lawyer, specializing in patent litigation for pharmaceutical companies. Holds a BS in Biology from Tel Aviv University, a dual degree from IDC in Finance and Law, and an MBA from Boston University.
Vladimir Slepushkin, MD, PhD – Chief Technology Officer
Global Head of Manufacturing at MedTherapy Biotechnology, leading all functions associated with manufacturing of CAR-T cells and viral vectors. Executive Director of Vector Technology at Autolus Therapeutics, leading process development for manufacturing of lentivirus vectors in suspension cell culture, guiding assay development to support process development for lentiviral vectors, managing CMO for GMP vector production and T-cell processing. Earlier, at Novartis Pharmaceutical, served as Director of CMC, Vector Design and Cell Line Development for CAR-T cancer gene therapy. Was also directing research vector core, and providing lentiviral, retroviral and AAV vectors for Kite Pharma, a CAR-T cell cancer gene therapy company. Developed novel high-quality products by managing diverse technical groups and cross-functional teams, developing first-in-class clinical product from scratch, including facilities, equipment, manufacturing process, quality systems, regulatory CMC submissions and clinical trials design. Proven expertise in technically understanding and leading the development and improvement of cell culture and purification processes, and operations and analytical methods, adhering to customer, regulatory, safety and environmental requirements and guidelines. Identified and resolved regulatory and manufacturing technical problems, as well as intellectual property assessment and licensing. Authored 61 scientific papers in peer- reviewed journals and he’s an author on 14 patents and patent applications. Ph.D. in Molecular Biology, from D.I. Ivanovsky Institute of Virology, Moscow, Russia. M.D. from Moscow Medical Institute, Moscow, Russia
James Blackwell, Ph.D. M.B.A – Head, Manufacturing (CMC)
Greatly accomplished clinical research scientist and executive who has served as President and Principal Consultant, Manager and scientist at many biotech and pharmaceuticals companies including The Windshire Group, Abbott Laboratories, Sanofi Genzyme, Repligen, BioProcess Technology Consultants, Inc. among others. Has long and impressive experience encompassing early process development to commercial operations for development, manufacturing, quality, regulatory, operations, and commercialization. Product experience includes all major therapeutic classes and sub-classes with clients including 1) Stabilityshire service for stability data analysis, reporting, and management; 2) Continued process verification for process and quality monitoring, trending, reporting, and data analysis, 3) RegDocs365 and ARCC (audit ready compliant cloud) quality systems; 4) Learningshire for learning solutions, 5) Assurashire for augmented, virtual quality and technical support through RegDocs365 and ARCC or on site presence. B.S.Ch.E. and MS education at Ohio State University, M.B.A./M.S. at University of Maryland University College, and PhD in Chemical Engineering at Northeastern University
Specific Risks
- Lack of adequate funding and investment into the Company
- Unanticipated or currently unknown factors causing supply chain disruption (e.g. COVID)
- Unknown constraints in availability of raw materials
- Competition
- Any other breakthrough advanced technology hitherto unknown
- Sudden burst in demand leading to capacity constraints in the interim
- Employees’ health
- Shortage of highly qualified manpower to be added
- Change in insurance policy coverage which would disallow patients in US to avail of this solution
- IT security breach
- IP violation by others
- Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment